Panel Design and Optimization for High‐Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry

2020 ◽  
Vol 92 (1) ◽  
Author(s):  
Laura Ferrer‐Font ◽  
Christophe Pellefigues ◽  
Johannes U. Mayer ◽  
Sam J. Small ◽  
Maria C. Jaimes ◽  
...  
2019 ◽  
Author(s):  
L Ferrer-Font ◽  
C Pellefigues ◽  
JU Mayer ◽  
S Small ◽  
MC Jaimes ◽  
...  

ABSTRACTTechnological advances in fluorescence flow cytometry and an ever-expanding understanding of the complexity of the immune system has led to the development of large 20+ flow cytometry panels. Yet, as panel complexity and size increases, so does the difficulty involved in designing a high-quality panel, accessing the instrumentation capable of accommodating large numbers of parameters, and in analysing such high-dimensional data.A recent advancement is spectral flow cytometry, which in contrast to conventional flow cytometry distinguishes the full emission spectrum of each fluorochrome across all lasers, rather than identifying only the peak of emission. Fluorochromes with a similar emission maximum but distinct off-peak signatures can therefore be accommodated within the same flow cytometry panel, allowing greater flexibility in terms of panel design and fluorophore detection.Here, we highlight the specific characteristics regarding spectral flow cytometry and aim to guide users through the process of building, designing and optimising high-dimensional spectral flow cytometry panels using a comprehensive step-by-step protocol. Special considerations are also given for using highly-overlapping dyes and a logical selection process an optimal marker-fluorophore assignment is provided.


2020 ◽  
Vol 97 (8) ◽  
pp. 824-831 ◽  
Author(s):  
Laura Ferrer‐Font ◽  
Johannes U. Mayer ◽  
Samuel Old ◽  
Ian F. Hermans ◽  
Jonathan Irish ◽  
...  

Bioanalysis ◽  
2021 ◽  
Author(s):  
Megan McCausland ◽  
Yi-Dong Lin ◽  
Tania Nevers ◽  
Christopher Groves ◽  
Vilma Decman

Flow cytometry is a powerful technology used in research, drug development and clinical sample analysis for cell identification and characterization, allowing for the simultaneous interrogation of multiple targets on various cell subsets from limited samples. Recent advancements in instrumentation and fluorochrome availability have resulted in significant increases in the complexity and dimensionality of flow cytometry panels. Though this increase in panel size allows for detection of a broader range of markers and sub-populations, even in restricted biological samples, it also comes with many challenges in panel design, optimization, and downstream data analysis and interpretation. In the current paper we describe the practices we established for development of high-dimensional panels on the Aurora spectral flow cytometer to aid clinical sample analysis.


2021 ◽  
Vol 12 ◽  
Author(s):  
Hannah den Braanker ◽  
Margot Bongenaar ◽  
Erik Lubberts

Spectral flow cytometry is an upcoming technique that allows for extensive multicolor panels, enabling simultaneous investigation of a large number of cellular parameters in a single experiment. To fully explore the resulting high-dimensional single cell datasets, high-dimensional analysis is needed, as opposed to the common practice of manual gating in conventional flow cytometry. However, preparing spectral flow cytometry data for high-dimensional analysis can be challenging, because of several technical aspects. In this article, we will give insight into the pitfalls of handling spectral flow cytometry datasets. Moreover, we will describe a workflow to properly prepare spectral flow cytometry data for high dimensional analysis and tools for integrating new data at later time points. Using healthy control data as example, we will go through the concepts of quality control, data cleaning, transformation, correcting for batch effects, subsampling, clustering and data integration. This methods article provides an R-based pipeline based on previously published packages, that are readily available to use. Application of our workflow will aid spectral flow cytometry users to obtain valid and reproducible results.


2013 ◽  
Vol 33 (21) ◽  
pp. 1, 20-21
Author(s):  
Kathy Liszewski
Keyword(s):  

2011 ◽  
Vol 363 (2) ◽  
pp. 245-261 ◽  
Author(s):  
Angélique Biancotto ◽  
John C. Fuchs ◽  
Ann Williams ◽  
Pradeep K. Dagur ◽  
J. Philip McCoy

2020 ◽  
Vol 93 (1) ◽  
Author(s):  
Caroline E. Roe ◽  
Madeline J. Hayes ◽  
Sierra M. Barone ◽  
Jonathan M. Irish

2021 ◽  
Vol 12 ◽  
Author(s):  
Paulina Valadez-Cosmes ◽  
Kathrin Maitz ◽  
Oliver Kindler ◽  
Sofia Raftopoulou ◽  
Melanie Kienzl ◽  
...  

Neutrophils have been described as a phenotypically heterogeneous cell type that possess both pro- and anti-tumor properties. Recently, a subset of neutrophils isolated from the peripheral blood mononuclear cell (PBMC) fraction has been described in cancer patients. These low-density neutrophils (LDNs) show a heterogeneous maturation state and have been associated with pro-tumor properties in comparison to mature, high-density neutrophils (HDNs). However, additional studies are necessary to characterize this cell population. Here we show new surface markers that allow us to discriminate between LDNs and HDNs in non-small cell lung cancer (NSCLC) patients and assess their potential as diagnostic/prognostic tool. LDNs were highly enriched in NSCLC patients (median=20.4%, range 0.3-76.1%; n=26) but not in healthy individuals (median=0.3%, range 0.1-3.9%; n=14). Using a high-dimensional human cell surface marker screen, we identified 12 surface markers that were downregulated in LDNs when compared to HDNs, while 41 surface markers were upregulated in the LDN subset. Using flow cytometry, we confirmed overexpression of CD36, CD41, CD61 and CD226 in the LDN fraction. In summary, our data support the notion that LDNs are a unique neutrophil population and provide novel targets to clarify their role in tumor progression and their potential as diagnostic and therapeutic tool.


2019 ◽  
Vol 143 (2) ◽  
pp. AB184
Author(s):  
Alberta GA. Paul ◽  
Jill Glesner ◽  
Josephine Lannigan ◽  
Lyndsey M. Muehling ◽  
Jacob D. Eccles ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document